Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,257 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Severity Assessment in CDKL5 Deficiency Disorder.
Demarest S, Pestana-Knight EM, Olson HE, Downs J, Marsh ED, Kaufmann WE, Partridge CA, Leonard H, Gwadry-Sridhar F, Frame KE, Cross JH, Chin RFM, Parikh S, Panzer A, Weisenberg J, Utley K, Jaksha A, Amin S, Khwaja O, Devinsky O, Neul JL, Percy AK, Benke TA. Demarest S, et al. Among authors: amin s. Pediatr Neurol. 2019 Aug;97:38-42. doi: 10.1016/j.pediatrneurol.2019.03.017. Epub 2019 Mar 27. Pediatr Neurol. 2019. PMID: 31147226 Free PMC article. Review.
Prophylactic Antiepileptic Treatment in Tuberous Sclerosis.
Choudhury P, Spaull R, Amin S, Mallick AA, Patel JS, O'Callaghan F, Lux AL. Choudhury P, et al. Among authors: amin s. Pediatr Neurol. 2020 Sep;110:100-101. doi: 10.1016/j.pediatrneurol.2020.03.017. Epub 2020 Apr 5. Pediatr Neurol. 2020. PMID: 32414624 No abstract available.
Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial.
Knight EMP, Amin S, Bahi-Buisson N, Benke TA, Cross JH, Demarest ST, Olson HE, Specchio N, Fleming TR, Aimetti AA, Gasior M, Devinsky O; Marigold Trial Group. Knight EMP, et al. Among authors: amin s. Lancet Neurol. 2022 May;21(5):417-427. doi: 10.1016/S1474-4422(22)00077-1. Lancet Neurol. 2022. PMID: 35429480 Clinical Trial.
International Consensus Recommendations for the Assessment and Management of Individuals With CDKL5 Deficiency Disorder.
Amin S, Monaghan M, Aledo-Serrano A, Bahi-Buisson N, Chin RF, Clarke AJ, Cross JH, Demarest S, Devinsky O, Downs J, Pestana Knight EM, Olson H, Partridge CA, Stuart G, Trivisano M, Zuberi S, Benke TA. Amin S, et al. Front Neurol. 2022 Jun 20;13:874695. doi: 10.3389/fneur.2022.874695. eCollection 2022. Front Neurol. 2022. PMID: 35795799 Free PMC article.
Growth patterns in individuals with CDKL5 deficiency disorder.
Wong K, Davies G, Leonard H, Downs J, Junaid M, Amin S. Wong K, et al. Among authors: amin s. Dev Med Child Neurol. 2024 Apr;66(4):469-482. doi: 10.1111/dmcn.15777. Epub 2023 Oct 7. Dev Med Child Neurol. 2024. PMID: 37804112
Long-term treatment with ganaxolone for seizures associated with cyclin-dependent kinase-like 5 deficiency disorder: Two-year open-label extension follow-up.
Olson HE, Amin S, Bahi-Buisson N, Devinsky O, Marsh ED, Pestana-Knight E, Rajaraman RR, Aimetti AA, Rybak E, Kong F, Miller I, Hulihan J, Demarest S. Olson HE, et al. Among authors: amin s. Epilepsia. 2024 Jan;65(1):37-45. doi: 10.1111/epi.17826. Epub 2023 Nov 29. Epilepsia. 2024. PMID: 37950390 Clinical Trial.
2,257 results